AC-262 357
Mild SARM — sometimes grouped with peptides in research catalogs.
Evidence
anecdotal
Legal status
research only
Half-life
~10 hours
Routes
oral
What it is
AC-262 357 is an oral non-steroidal SARM developed for benign prostatic hyperplasia. Anabolic effect is moderate with a reportedly favorable side-effect profile vs traditional androgens.
Mechanism
Tissue-selective androgen receptor partial agonist.
Outcomes it's matched to
- STRENGTH50%
Safety
HPTA suppression possible.
- Pregnancy
Legal context
Research use only. WADA-prohibited.